GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (MEX:AMG N) » Definitions » Cyclically Adjusted PS Ratio

Amgen (MEX:AMG N) Cyclically Adjusted PS Ratio : 5.14 (As of Jun. 27, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Amgen Cyclically Adjusted PS Ratio?

As of today (2025-06-27), Amgen's current share price is MXN5258.00. Amgen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN1,023.89. Amgen's Cyclically Adjusted PS Ratio for today is 5.14.

The historical rank and industry rank for Amgen's Cyclically Adjusted PS Ratio or its related term are showing as below:

MEX:AMG N' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 5.09   Med: 7.18   Max: 9.31
Current: 5.63

During the past years, Amgen's highest Cyclically Adjusted PS Ratio was 9.31. The lowest was 5.09. And the median was 7.18.

MEX:AMG N's Cyclically Adjusted PS Ratio is ranked worse than
82.3% of 740 companies
in the Drug Manufacturers industry
Industry Median: 2.13 vs MEX:AMG N: 5.63

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Amgen's adjusted revenue per share data for the three months ended in Mar. 2025 was MXN308.159. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN1,023.89 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Amgen Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Amgen's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Cyclically Adjusted PS Ratio Chart

Amgen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.25 6.17 6.42 6.50 5.39

Amgen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.22 6.69 6.78 5.39 6.28

Competitive Comparison of Amgen's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted PS Ratio falls into.


;
;

Amgen Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Amgen's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=5258.00/1023.89
=5.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Amgen's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=308.159/134.9266*134.9266
=308.159

Current CPI (Mar. 2025) = 134.9266.

Amgen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 109.709 100.684 147.021
201509 126.580 100.392 170.124
201512 124.760 99.792 168.685
201603 125.187 100.470 168.120
201606 139.142 101.688 184.623
201609 149.215 101.861 197.652
201612 165.742 101.863 219.541
201703 138.842 102.862 182.122
201706 142.306 103.349 185.786
201709 142.931 104.136 185.193
201712 156.954 104.011 203.606
201803 141.917 105.290 181.864
201806 180.388 106.317 228.930
201809 170.161 106.507 215.566
201812 190.836 105.998 242.919
201903 172.196 107.251 216.631
201906 184.878 108.070 230.823
201909 188.139 108.329 234.331
201912 195.771 108.420 243.633
202003 243.204 108.902 301.324
202006 241.972 108.767 300.168
202009 240.901 109.815 295.989
202012 225.965 109.897 277.430
202103 207.612 111.754 250.660
202106 225.532 114.631 265.462
202109 241.910 115.734 282.026
202112 249.005 117.630 285.621
202203 225.417 121.301 250.738
202206 247.036 125.017 266.618
202209 248.708 125.227 267.973
202212 247.831 125.222 267.038
202303 204.540 127.348 216.713
202306 223.030 128.729 233.768
202309 223.499 129.860 232.220
202312 258.589 129.419 269.593
202403 230.583 131.776 236.096
202406 284.046 132.554 289.131
202409 308.905 133.029 313.312
202412 350.268 133.157 354.923
202503 308.159 134.927 308.159

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Amgen  (MEX:AMG N) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Amgen Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Amgen's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen Business Description

Industry
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Headlines

No Headlines